We provide you with 20 years of free, institutional-grade data for GRPH stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GRPH. Explore the full financial landscape of GRPH stock.
| Reported Date | CIK | Ticker | Type |
|---|
Graphite Bio Inc(NASDAQ:GRPH) 
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH30...
The information provided in this report about GRPH stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.